PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 16.05 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cara Therapeutics Inc | CARA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.29 | -1.77% | 16.05 | 16.442 | 15.93 | 16.35 | 16.34 | 23:59:44 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 10.12 | 25.00 | 14.88 | 59.52% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,871 | 506,858 | $ 16.11 | $ 8,164,101 | 730,718 | 14.10 - 27.55 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:29:14 | 1 | $ 16.00 | USD |
Cara Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 749.20M | 46.68M | $ -74.01M | -2.06 | - | 45.26M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cara Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/08/2020 | 16:01 | GlobeNewswire Inc. | Cara Therapeutics to Present at the 38th Annual J.P. Morgan.. |
| 1/06/2020 | 18:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/06/2020 | 18:06 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/30/2019 | 18:07 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/23/2019 | 08:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/16/2019 | 06:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/10/2019 | 14:19 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CARA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.05 | 18.32 | 15.73 | 16.69 | 844,566 | -1.00 | -5.87% |
| 1 Month | 16.58 | 18.32 | 14.775 | 16.07 | 689,114 | -0.53 | -3.2% |
| 3 Months | 20.68 | 26.67 | 14.775 | 17.92 | 767,883 | -4.63 | -22.39% |
| 6 Months | 25.40 | 26.67 | 14.775 | 19.94 | 703,497 | -9.35 | -36.81% |
| 1 Year | 15.03 | 27.55 | 14.10 | 19.85 | 712,253 | 1.02 | 6.79% |
| 3 Years | 11.97 | 28.50 | 11.11 | 17.02 | 1,100,095 | 4.08 | 34.09% |
| 5 Years | 10.63 | 28.50 | 4.26 | 15.05 | 898,161 | 5.42 | 50.99% |
Cara Therapeutics Description
| Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |
